Table 2.
Baseline characteristics of individuals who held the MyDiagnostick divided in new screen-detected cases of AF, patients already known with AF, and a random sample of patients with no AF
| Newly detected AF with screening N = 37 |
Already known with AF and a red light with screening N = 84 |
Sample of patients with no AFa N = 220 |
|
|---|---|---|---|
| Men (%) | 21 (56.8) | 49 (58.3) | 101 (45.9) |
| Mean age (SD) | 75.9 (8.6) | 75.6 (8.3) | 65.9 (12.4) |
| Medical history | |||
| Hypertension (%) | 24 (64.9) | 55 (65.5) | 95 (43.2) |
| Diabetes (%) | 9 (24.3) | 23 (27.4) | 52 (23.6) |
| Heart failure (%) | 2 (5.4) | 18 (21.4) | 2 (0.9) |
| Stroke (%)b | 7 (18.9) | 9 (10.7) | 6 (2.7) |
| TIA (%) | 3 (8.1) | 10 (11.9) | 1 (0.5) |
| VTE (%)c | 2 (5.4) | 7 (14.3) | 10 (4.5) |
| Peripheral arterial disease (%) | 3 (8.1) | 2 (2.4) | 7 (3.2) |
| Prior myocardial infarct (%) | 2 (5.4) | 10 (14.3) | 7 (3.2) |
| Valvular repair (%) | 0 (0) | 6 (7.1) | 1 (0.5) |
| CABG/PCI (%) | 2 (5.4) | 14 (16.7) | 19 (8.6) |
| COPD (%) | 4 (10.8) | 12 (17.1) | 17 (7.7) |
| Renal disease (%) | 3 (8.1) | 11 (15.7) | 8 (3.6) |
| Pacemaker (%) | 0 (0.0) | 4 (4.8) | 2 (0.9) |
| Vitamin K antagonists (%) | 2 (5.4)d | 70 (83.3) | 5 (2.3)d |
| NOACs (%) | 0 (0.0) | 7 (8.3) | 0 (0.0) |
| ASA (%) | 11 (29.7) | 7 (8.3) | 46 (20.9) |
| ACE inhibitors (%) | 10 (27.0) | 31 (36.9) | 55 (25.0) |
| Beta-blockers (%) | 8 (21.6) | 59 (70.2) | 58 (26.4) |
| Calcium channel blockers (%) | 13 (35.1) | 21 (25.0) | 27 (12.3) |
aSample of 220 persons unknown with AF and also sinus rhythm on the MyDiagnostick single-lead ECG with screening during influenza vaccination.
bStroke is defined as ischaemic stroke or cryptogenic stroke not being an haemorrhagic infarction.
cVTE = venous thromboembolism, including history of pulmonary embolism and/or deep vein thrombosis.
dIndications for VKA in two cases was (1) a history of deep vein thrombosis and lung embolus, and a history of ischaemic stroke. The indications in five cases with a negative MyDiagnostick result were (1) a history of more than one deep vein thrombosis or lung embolus, (2) heart valve replacement, and (3) secondary prevention after ischaemic stroke.
NOAC, non-vitamin K antagonist oral anticoagulant.